vs
Amphastar Pharmaceuticals, Inc.（AMPH）とGIBRALTAR INDUSTRIES, INC.（ROCK）の財務データ比較。上の社名をクリックして会社を切り替えられます
GIBRALTAR INDUSTRIES, INC.の直近四半期売上が大きい（$225.0M vs $183.1M、Amphastar Pharmaceuticals, Inc.の約1.2倍）。GIBRALTAR INDUSTRIES, INC.の前年同期比売上増加率が高い（24.9% vs -1.8%）。GIBRALTAR INDUSTRIES, INC.の直近四半期フリーキャッシュフローが多い（$26.2M vs $24.6M）。過去8四半期でAmphastar Pharmaceuticals, Inc.の売上複合成長率が高い（3.2% vs -12.3%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
ジブラルタル・インダストリーズ社は、特殊建築資材、インフラ関連製品、再生可能エネルギー向け製品の製造・販売を行う有力企業です。換気システム、屋根用付属品、太陽光発電設置架台、造園用品などを取り扱い、主に北米の住宅・商業建設、クリーンエネルギー市場向けにサービスを提供しています。
AMPH vs ROCK — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $225.0M |
| 純利益 | $24.4M | — |
| 粗利率 | 46.8% | 25.3% |
| 営業利益率 | 19.4% | 7.9% |
| 純利益率 | 13.3% | — |
| 売上前年比 | -1.8% | 24.9% |
| 純利益前年比 | -35.7% | — |
| EPS（希薄化後） | $0.51 | — |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $183.1M | $225.0M | ||
| Q3 25 | $191.8M | $310.9M | ||
| Q2 25 | $174.4M | $309.5M | ||
| Q1 25 | $170.5M | $290.0M | ||
| Q4 24 | $186.5M | $180.1M | ||
| Q3 24 | $191.2M | $277.1M | ||
| Q2 24 | $182.4M | $273.6M | ||
| Q1 24 | $171.8M | $292.5M |
| Q4 25 | $24.4M | — | ||
| Q3 25 | $17.4M | $-89.1M | ||
| Q2 25 | $31.0M | $26.0M | ||
| Q1 25 | $25.3M | $21.1M | ||
| Q4 24 | $38.0M | — | ||
| Q3 24 | $40.4M | $34.0M | ||
| Q2 24 | $37.9M | $32.2M | ||
| Q1 24 | $43.2M | $24.9M |
| Q4 25 | 46.8% | 25.3% | ||
| Q3 25 | 51.4% | 26.6% | ||
| Q2 25 | 49.6% | 28.4% | ||
| Q1 25 | 50.0% | 26.8% | ||
| Q4 24 | 46.5% | 29.0% | ||
| Q3 24 | 53.3% | 29.4% | ||
| Q2 24 | 52.2% | 30.5% | ||
| Q1 24 | 52.4% | 28.9% |
| Q4 25 | 19.4% | 7.9% | ||
| Q3 25 | 13.2% | 12.8% | ||
| Q2 25 | 24.2% | 12.8% | ||
| Q1 25 | 21.9% | 8.8% | ||
| Q4 24 | 24.2% | 13.3% | ||
| Q3 24 | 29.8% | 15.6% | ||
| Q2 24 | 30.3% | 14.9% | ||
| Q1 24 | 27.9% | 10.8% |
| Q4 25 | 13.3% | — | ||
| Q3 25 | 9.0% | -28.6% | ||
| Q2 25 | 17.8% | 8.4% | ||
| Q1 25 | 14.8% | 7.3% | ||
| Q4 24 | 20.4% | — | ||
| Q3 24 | 21.1% | 12.3% | ||
| Q2 24 | 20.8% | 11.8% | ||
| Q1 24 | 25.1% | 8.5% |
| Q4 25 | $0.51 | — | ||
| Q3 25 | $0.37 | $-2.98 | ||
| Q2 25 | $0.64 | $0.87 | ||
| Q1 25 | $0.51 | — | ||
| Q4 24 | $0.74 | — | ||
| Q3 24 | $0.78 | $1.11 | ||
| Q2 24 | $0.73 | $1.05 | ||
| Q1 24 | $0.81 | — |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $115.7M |
| 総負債低いほど良い | $608.7M | $0 |
| 株主資本純資産 | $788.8M | $950.4M |
| 総資産 | $1.6B | $1.4B |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | 0.00× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $282.8M | $115.7M | ||
| Q3 25 | $276.2M | $89.4M | ||
| Q2 25 | $231.8M | $43.3M | ||
| Q1 25 | $236.9M | $25.1M | ||
| Q4 24 | $221.6M | $269.5M | ||
| Q3 24 | $250.5M | $228.9M | ||
| Q2 24 | $217.8M | $179.1M | ||
| Q1 24 | $289.6M | $146.7M |
| Q4 25 | $608.7M | $0 | ||
| Q3 25 | $608.6M | $0 | ||
| Q2 25 | $607.7M | $0 | ||
| Q1 25 | $603.9M | $0 | ||
| Q4 24 | $601.6M | $0 | ||
| Q3 24 | $596.4M | $0 | ||
| Q2 24 | $586.9M | $0 | ||
| Q1 24 | $594.0M | $0 |
| Q4 25 | $788.8M | $950.4M | ||
| Q3 25 | $776.7M | $951.8M | ||
| Q2 25 | $757.5M | $1.0B | ||
| Q1 25 | $751.3M | $1.0B | ||
| Q4 24 | $732.3M | $1.0B | ||
| Q3 24 | $727.7M | $1.0B | ||
| Q2 24 | $713.3M | $975.7M | ||
| Q1 24 | $672.4M | $940.2M |
| Q4 25 | $1.6B | $1.4B | ||
| Q3 25 | $1.7B | $1.4B | ||
| Q2 25 | $1.6B | $1.5B | ||
| Q1 25 | $1.6B | $1.4B | ||
| Q4 24 | $1.6B | $1.4B | ||
| Q3 24 | $1.5B | $1.4B | ||
| Q2 24 | $1.5B | $1.4B | ||
| Q1 24 | $1.6B | $1.3B |
| Q4 25 | 0.77× | 0.00× | ||
| Q3 25 | 0.78× | 0.00× | ||
| Q2 25 | 0.80× | 0.00× | ||
| Q1 25 | 0.80× | 0.00× | ||
| Q4 24 | 0.82× | 0.00× | ||
| Q3 24 | 0.82× | 0.00× | ||
| Q2 24 | 0.82× | 0.00× | ||
| Q1 24 | 0.88× | 0.00× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $35.5M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | $26.2M |
| FCFマージンFCF / 売上 | 13.4% | 11.7% |
| 設備投資強度設備投資 / 売上 | 4.5% | 4.1% |
| キャッシュ転換率営業CF / 純利益 | 1.35× | — |
| 直近12ヶ月FCF直近4四半期 | $121.2M | $120.6M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $32.9M | $35.5M | ||
| Q3 25 | $52.6M | $73.0M | ||
| Q2 25 | $35.6M | $44.9M | ||
| Q1 25 | $35.1M | $13.7M | ||
| Q4 24 | $29.0M | $19.9M | ||
| Q3 24 | $60.0M | $64.7M | ||
| Q2 24 | $69.1M | $36.5M | ||
| Q1 24 | $55.3M | $53.2M |
| Q4 25 | $24.6M | $26.2M | ||
| Q3 25 | $47.2M | $64.8M | ||
| Q2 25 | $25.0M | $27.3M | ||
| Q1 25 | $24.4M | $2.3M | ||
| Q4 24 | $16.6M | $14.1M | ||
| Q3 24 | $46.2M | $60.5M | ||
| Q2 24 | $63.1M | $33.5M | ||
| Q1 24 | $46.5M | $48.8M |
| Q4 25 | 13.4% | 11.7% | ||
| Q3 25 | 24.6% | 20.8% | ||
| Q2 25 | 14.3% | 8.8% | ||
| Q1 25 | 14.3% | 0.8% | ||
| Q4 24 | 8.9% | 7.8% | ||
| Q3 24 | 24.1% | 21.8% | ||
| Q2 24 | 34.6% | 12.2% | ||
| Q1 24 | 27.1% | 16.7% |
| Q4 25 | 4.5% | 4.1% | ||
| Q3 25 | 2.8% | 2.6% | ||
| Q2 25 | 6.1% | 5.7% | ||
| Q1 25 | 6.3% | 3.9% | ||
| Q4 24 | 6.7% | 3.3% | ||
| Q3 24 | 7.2% | 1.5% | ||
| Q2 24 | 3.3% | 1.1% | ||
| Q1 24 | 5.1% | 1.5% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | 1.73× | ||
| Q1 25 | 1.39× | 0.65× | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | 1.90× | ||
| Q2 24 | 1.82× | 1.13× | ||
| Q1 24 | 1.28× | 2.13× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
ROCK
| Transferred At Point In Time | $183.5M | 82% |
| Infrastructure | $22.5M | 10% |
| Other | $18.9M | 8% |
